Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study.

Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Abstract Text:

    shoji sanadaShoji Sanada,hiroshi asanumaHiroshi Asanuma,yukihiro koretsuneYukihiro Koretsune,kouki watanabeKouki Watanabe,shinsuke nantoShinsuke Nanto,nobuhisa awataNobuhisa Awata,noritake hokiNoritake Hoki,masatake fukunamiMasatake Fukunami,masafumi kitakazeMasafumi Kitakaze,masatsugu horiMasatsugu Hori,shoji sanadaShoji Sanada,hiroshi asanumaHiroshi Asanuma,yukihiro koretsuneYukihiro Koretsune,kouki watanabeKouki Watanabe,shinsuke nantoShinsuke Nanto,nobuhisa awataNobuhisa Awata,noritake hokiNoritake Hoki,masatake fukunamiMasatake Fukunami,masafumi kitakazeMasafumi Kitakaze,masatsugu horiMasatsugu Hori,

    Adenosine is known as an endogenous cardioprotectant. We previously reported that plasma adenosine levels increase in patients with chronic heart failure (CHF), and that a treatment that further elevates plasma adenosine levels may improve the pathophysiology of CHF. Therefore, we performed a prospective, open-randomized clinical trial to determine whether or not exposure to dipyridamole for 1 year improves CHF pathophysiology compared with conventional treatments. The study enrolled 28 patients (mean+/-SEM: 66+/-4 years of age) attending specialized CHF outpatient clinics with New York Heart Association (NYHA) class II or III, no major complications, and stable CHF status during the most recent 6 months under fixed medications. They were randomized into three groups with or without dipyridamole (Control: n=9; 75 mg/day: n=9; 300 mg/day: n=10) in addition to their original medications and were followed up for 1 year. The other drugs were not altered. Among the enrolled patients, 100%, 4%, 100%, and 79% received angiotensin-converting enzyme inhibitors, aldosterone analogue, loop diuretics, and beta-adrenoceptor blocker, respectively. Fifteen patients suffered from dilated cardiomyopathy, and 7/3/3 patients suffered from ischemic/valvular/hypertensive heart diseases, respectively. Mean blood pressure was comparable among the groups. While the baseline conditions were comparable, we found that echocardiographic ejection fraction (p<0.01 vs. baseline, p<0.01 vs. Control), left ventricular systolic diameter (p<0.05, p<0.05), Specific Activity Scale (SAS) score (p<0.05, p<0.01), maximal oxygen consumption (p<0.05, p<0.05) and plasma B-type natriuretic peptide level (p<0.01, p<0.01) were significantly improved in patients with dipyridamole after 1 year, generally in a dose-dependent manner. Therefore, we suggest that an additional administration of dipyridamole further improves CHF pathophysiology.

    Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Publishing Authors By Initials

    s sanadaS Sanada,h asanumaH Asanuma,y koretsuneY Koretsune,k watanabeK Watanabe,s nantoS Nanto,n awataN Awata,n hokiN Hoki,m fukunamiM Fukunami,m kitakazeM Kitakaze,m horiM Hori,s sanadaS Sanada,h asanumaH Asanuma,y koretsuneY Koretsune,k watanabeK Watanabe,s nantoS Nanto,n awataN Awata,n hokiN Hoki,m fukunamiM Fukunami,m kitakazeM Kitakaze,m horiM Hori,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: Hypertension research : official journal of the Ja

    VOLUME: 30

    Page Numbers: 913-9

    Journal Abbreviation: Hypertens. Res.

    ISSN: 0916-9636

    DAY: 30

    MONTH: Oct

    YEAR: 2007

    Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9307690

    Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study.

    AFFILIATION: Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

    Country: Japan

    Japan Research PublicationJapan Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Hypertens Res

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Long-term oral administration of dipyridamole improves both cardiac and physical status in patients with mild to moderate chronic heart failure: a prospective open-randomized study Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News